Buradasınız

Anasayfa » Content

KISA SÜRE UYGULANAN (8 HAFTA) REKOMBİNANT HUMAN ERİTROPOETİN'İN (r-HuEPO) HEMODİYALİZ HASTALARINDAKİ HEMATOLOJİK VE BİYOKİMYASAL PARAMETRELERE ETKİSİ

THE EFFECTS ON THE HEMATOLOGIC AND BIOCHEMICAL PARAMETERS OF A SHORT COURSE (8 WEEKS) (r-HuEPO) TREATMENT IN HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The effects on the hematologic and biochemical parameters of short course r-HuEPO treatment (Sweeks) in hemodialysis patients r-HuEPO was administered to 20 patients who receiving chronic hemodialysis treatment diagnosed end-stage renal diseases. Each patient received a dose of 50ü/kg r-HuEPO after hemodialysis three times weekly, as an intravenous bolus, by 8 week. After treatment,mean Hb. and Htc. levels ranged from 6.2±_1.6 g to 7.9±1.5 g and from 20.5±5.7 percent to 25.5±5.5 percent, respectively. Similarly, we observed that increases in reticulocytes and erythrocytes levels were statistically significant. No differences in serum iron, serum iron binding capasity, leucocytes, peripheral blood smear, biochemical parameters and both systolic and diastolic pressures determined. Treatment was stopped in two patients due to renal transplantation and severe bone pains.
Bookmark/Search this post with
Abstract (Original Language): 
r-HuEPO, Son Dönem Böbrek Yetmezliği (SDBY) tanısıyla Kronik Hemodiyaliz, programında olan 20 olguya uygulandı.8 hafta süreylejıaftada 3 kez, ve hemodiyaliz, sonrasında 50 ü/kg doz,ıında,i.v. bolüs şeklinde r-HuEPO verildi.Tedavi öncesinde ortalama Hemoglo¬bin (Hb) düzeyi 6.2±1.6 gr, ortalama Hematokrit(Htc) düzeyi %20.5±_5.7 iken tedavi sonrasında, ortalama Hb:7.9±1.5gr'a,ortalama Htc:%25.5±5.5a çıktı. Aynı şekilde Retikülosit ve Eritrosit değerlerinde de istatik-sel anlamlı artışlar gözlendi. Serum Demir'i(Fe),serum Demir Bağlama Kapasitesi(FeBağ), Lökosit, Lökosit formülüjBiyokimyasal parametreler ve sistolik-diyasto-lik arter basınçlarında değişiklik saptanmadı.Çalışma grubundaki 1 olguda Renal Transplantasyon, 1 olgu¬da da şiddetli kemik ağrıları nedeniyle tedavi kesildi.
FULL TEXT (PDF): 
PDF icon pdf_tndt_47.pdf
  • 2
45-48
  • Turkish

REFERENCES

References: 

1- Eschbach J.W.The Anemia of Chronic Renal Failure:Pat-hophysiology and the Effects of Recombinant Erytropoietin Kidney Int.35:134-148,1989.
2- Faulds D,Sorkin E.M;r-HuEPO(Recombinant Human Erythropoietin'' Review of its Pharmacodynamic and Pharmacoki-netic properties and Therapeutic Potential in Anemia and the Stimulation of Erythropoiesis Drugs 6:863-899,1989.
3- Kurtzmann N.A; Recombinant Human Erytropoietin Therapy
PartILPatient Management Seminars in Nefhrology.9;l,
Suppl.2: 1-31, 1989.
4- Mota M, Vizzotto L, Cattaneo M, Manucci P.M,Improvement in the Heamostatic Deffect of Uraemia After Treatment with Recombinant Human Erythropoietin.The Lancet, 28: 1227-1229,1987.
5- Schaefer R.M.Horld W.H,Massry S.G;Treatment of Renal
Anemia with Recombinant Human Erythropoietin Am.J.Nefh-rology,9:353-362, 1989.
6- Bommer C.Alexiu U, Müller-Bühl J, Eifert J.Ritz E:Recombi-nant Human Erythropoietin Therapy in Haemodialysis Pati¬ents-Dose Determination and Clinical Experience Nephrol Di¬al Transplant 2:238-242,1987.
7- Casati S,Campise M, Crepaldi M, Lobo J: Heamodialysis Effi¬ciency After Long-Term Treatment with Recombinant Human
Erytropoietin. Nephrol Dial Transplant 4L:718-720, 1989.
8- Mat,O, Stolear, J.C, Georges, B:Blood Lipid Profile in Hemo-dialysis Patients Treated with Human Erythropoetin(84 years on Hemodialysis) XXIX.th Congress of the European Dialysis and Transplant Association Abstracts.p: 196-1992.
9- Viron,B,Donsimoni, R, Michel, C.et al.Effect of Recombinant Human Erytropoetin on Nutrional Status and Plazma Lipid in
Uremic Patients Nephron 60,249,1992.
10- Cozma G, r-HuEPO(EPREX) Therapy and blood Pressure
Bio-News Scientific Cilag.22:l-5,1992.
11- Ono K.Hisasue Y, THE Rate of Increase in Hematocrit.Hu-moral Vasoactive Substances and Blood Pressure Canges in Hemodialysis. Patients Treated with Recombinant Human Erytropoietin or Blood Transfusion Excerpta Medica, 4:50-51,1992.
12- Teehan B, Heematologic and Physiologic Studies in Prediasly-sis Patients receiving Recombinant Human Erytropoietin Di¬alysis &Transplantation, 17:636-639,198

Thank you for copying data from http://www.arastirmax.com